Breaking News: Cybin Inc. (NYSE: CYBN) Finalizes Share Consolidation – Leaving Under 16M in Public Float

Market Crux Announces Its Next Exclusive Profile! Start Your Research on Cybin Inc. (NYSE American: CYBN)! Cybin Inc. (NYSE American: CYBN) Comes Backed by Several Potential  Catalyst Including: Major Share Consolidation on Deck Today for Cybin Inc. (NYSE: CYBN). Limited Float: Cybin Inc. (NYSE: CYBN) Now Has Less Than 16M in Float Post Consolidation! Analyst Coverage: HC Wainwright & Co. recently reiterated a target for Cybin (CYBN), suggesting a potential upside of 2,300%! FDA Designation: Cybin (CYBN)’s CYB003 received FDA Breakthrough Therapy status, expediting its development for depression treatment. Mental Health Innovation: Cybin (CYBN) leads in developing next-gen psychedelic therapies for depression and anxiety. R&D Focus: Advancing CYB003 (MDD) and CYB004 (GAD) programs, driving new mental health treatments. Clinical Pipeline: Phase 3 trial for CYB003 begins in summer 2024, following 75% remission success in Phase 2. Global Reach: Operating in key markets (U.S., UK, EU), boosting clinical partnerships and goals. Strong IP: Cybin (CYBN)’s Cybin’s U.S. patent for CYB004 secures long-term competitive advantage. Severely Oversold Territory: Cybin (CYBN) appears to be entering severely oversold territory, with low RSI levels suggesting the potential for a trend reversal. September 19, 2024 Dear Reader, This morning, Cybin Inc. (NYSE: CYBN) announced the completion of its 1-for-38 share consolidation. Outstanding shares have been reduced to approximately 19,991,907, with a float of 15.37M according to Yahoo.  The consolidation is now in effect.  See full article here. The company recently held a special meeting on 8/27, where the board of directors approved a share reduction that could potentially shrink the float from approximately 574.01M shares to less than 16M using the 38-1 ratio. With this low float scenario, market conditions could shift quickly, making Cybin Inc. (NYSE American: CYBN) a company to watch closely today. Beyond its share structure changes, Cybin's clinical focus has also been attracting significant attention. The U.S. FDA has now designated psi-lo-cy-bin, a classical compound found in "ma-gic mush-rooms," as a "breakthrough therapy" for the treatment of major depressive disorder three times.  In London, the world’s largest clinical trial into the use of psi-lo-cyb-in for treating depression is being hailed as a "milestone" in mental health research.  This new frontier in treatment has sparked a Multi-Trln-Dollar industry focused on innovative therapeutics for mental health. Johnson & Johnson has fully embraced this trend, with its leading treatment for depression becoming the only FDA-approved psychedelic-based therapy on the market. In their Q4 earnings report last year, Johnson & Johnson noted a remarkable 74.1% increase in global sales and views this treatment as a future Bln-Dollar product. Some of the core team members behind the development of this groundbreaking therapy have now joined a little-known, yet emerging NYSE American-listed company, Cybin Inc. (NYSE American: CYBN).  Cybin Inc. (NYSE American: CYBN) is pioneering next-generation therapeutics aimed at addressing the unmet needs of people suffering from mental health challenges. But let's get right into why I'm bringing Cybin Inc. (NYSE American: CYBN) to your attention now.  Cybin Inc. (NYSE American: CYBN) appears to be entering a severely oversold territory, according to technical indicators.  A Relative Strength Index (RSI) value below 30 typically signals such a scenario, and with Cybin Inc. (NYSE American: CYBN)’s RSI levels at 9-Day: 9.69%, 14-Day: 14.39%, and 20-Day: 19.88%, the data points to a potential trend reversal.  After setting a new 52-week low of $.1739 on 9/5/2024, shares of Cybin Inc. (NYSE American: CYBN) moved approximately 24% in less than 24-hours, reaching $.2163 on 9/6/2024.  But that’s not all—as reported by Benzinga, on 8/23/2024, HC Wainwright & Co., one of Wall Street’s oldest and most respected firms, reiterated a target for (CYBN), suggesting a potential upside of approximately 2,300% from this morning's opening price of $.2011. Keep reading to discover why Cybin Inc. (NYSE American: CYBN) should be on your radar. Cybin Inc. (NYSE American: CYBN) is at the forefront of innovation in the mental health space, focusing on creating next-generation therapeutics to address the substantial unmet needs of those suffering from mental health conditions.  As a clinical-stage company, Cybin Inc. (NYSE American: CYBN)’s mission is to develop safe and effective treatment options that could transform the way neuropsychiatric disorders are treated.  Headquartered in Canada and founded in 2019, Cybin Inc. (NYSE American: CYBN) operates across several countries, including the United States, the United Kingdom, the Netherlands, and Ireland, leveraging an impressive global footprint to advance its clinical objectives. Pioneering Treatments for Mental Health Disorders Cybin Inc. (NYSE American: CYBN) is advancing its two flagship programs: CYB003 and CYB004, aimed at addressing Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively.  These programs reflect Cybin’s commitment to leveraging psychedelic-based compounds and cutting-edge research to develop novel therapeutic approaches. - CYB003 is a proprietary deuterated psi-lo-cy-bin analog designed to treat MDD. The company has made significant strides in advancing this program, with plans to initiate a Phase 3 pivotal trial in late summer 2024. - CYB004 is a proprietary deuterated DMT (dDMT) molecule under development for the treatment of GAD. The program is also advancing with Phase 2 trials underway, demonstrating Cybin's ability to target multiple neuropsychiatric conditions with innovative approaches. Advancing Clinical Development: Recent Milestones and Future Directions Cybin Inc. (NYSE American: CYBN) recently completed a critical FDA Type B Initial Breakthrough Therapy Meeting, setting the stage for the launch of its Phase 3 pivotal trial for CYB003 in late summer 2024.  This study, which will take place across 30 clinical sites in the U.S. and Europe, aims to build upon the promising results from Phase 2, where 75% of patients entered remission from depression four months after receiving two 16 mg doses of CYB003.  With its sights set on becoming a trailblazer in neuropsychiatry, Cybin Inc. (NYSE American: CYBN)’s focus on long-term efficacy data underscores its dedication to developing durable solutions for mental health treatment. To tackle potential issues such as functional unblinding, Cybin Inc. (NYSE American: CYBN)’s Phase 3 trial will feature rigorous design elements, including: - A three-arm study with high-dose, mid-dose, and placebo groups to reduce expectancy bias. - Independent, blinded raters with no knowledge of dosing information. - Participants who are largely psychedelic naïve to minimize the impact of prior experience. - AI screening technologies to enhance patient monitoring and ensure data integrity. Research Pipeline and Global Collaborations Cybin Inc. (NYSE American: CYBN)’s success is supported by a network of world-class partners and internationally recognized scientists.  This collaborative framework has enabled the company to create proprietary dr-ug discovery platforms and innovative dr-ug delivery systems, propelling the development of psychedelic-based investigational compounds for treating complex mental health conditions.  The company’s novel approach to formulation and treatment regimens offers the potential to reshape mental healthcare, with a focus on developing patient-friendly treatments that are both effective and safe. Recent Business Developments and Fiscal Health Cybin Inc. (NYSE American: CYBN)’s recent financial report for the first quarter of fiscal year 2025 highlights the company's solid financial position and commitment to advancing its clinical pipeline: - The company reported ca-sh reserves totaling C$183 million as of June 30, 2024, providing a strong financial foundation to support its ambitious clinical development programs. - Despite reporting a net loss of C$15 million for the quarter, Cybin's cash-based operating expenses, particularly in research and development, highlight its investment in long-term growth. - With ongoing funding from public offerings and anticipated ca-sh access exceeding C$247 million, Cybin is well-positioned to navigate the next phases of its clinical journey. Strengthening Leadership and R&D Capabilities To lead its breakthrough programs, Cybin has enhanced its leadership team with the appointment of two highly experienced dr-ug development professionals: - Dr. Atul R. Mahableshwarkar has been named Senior Vice President of Clinical Development and will oversee the CYB003 program. Dr. Mahableshwarkar brings a wealth of experience in neuropsychiatry and dr-ug approvals. - Dr. Tom Macek joins Cybin as Senior Vice President of Clinical Development for the CYB004 program. His extensive background in pharmaceutical development will help accelerate progress in treating GAD with CYB004. Strategic Intellectual Property and Patent Milestones A key component of Cybin Inc. (NYSE American: CYBN)’s growth strategy is the protection of its intellectual property.  In July 2024, Cybin was granted U.S. patent no. 12,042,564, further strengthening its CYB004 program.  This patent underscores the company’s ability to protect its proprietary formulations and delivery systems, ensuring its innovations are well-positioned for commercialization. Looking Ahead: Upcoming Milestones Cybin has an ambitious roadmap, with multiple clinical milestones on the horizon: - Phase 3 trials for CYB003 in MDD are set to begin in late summer 2024, marking a major step toward regulatory approval and commercialization. - 12-month efficacy data from the Phase 2 CYB003 study is expected in Q4 2024, providing crucial insights into its long-term benefits for depression. - Topline safety and efficacy results for CYB004 in GAD are anticipated by year-end 2024 or early 2025, adding momentum to Cybin's quest to bring new treatment options to market. As a clinical-stage company dedicated to revolutionizing mental health treatment, Cybin Inc. (NYSE American: CYBN) is strategically positioning itself to address some of the most pressing needs in neuropsychiatry.  With a robust pipeline, a world-class leadership team, and cutting-edge research efforts, Cybin Inc. (NYSE American: CYBN) is moving swiftly toward delivering breakthrough therapeutics that could transform the mental health landscape.  By focusing on innovative, psychedelic-based compounds and strategically advancing clinical trials, Cybin Inc. (NYSE American: CYBN) is at the forefront of creating new, life-changing treatment options for millions of people struggling with mental health disorders. Here are 7 reasons to add Cybin Inc. (NYSE American: CYBN) to your watchlist...… 1. Share Consolidation: Cybin Inc. (NYSE American: CYBN)’s highly anticipated 1-for-38 share consolidation, set to take place today, could shake things up! With the float potentially shrinking from 574.01M shares to less than 15.2M, this drastic reduction could ignite significant shifts in market dynamics, making this one company you won't want to take your eyes off of! 2. Analyst Coverage: With top firms like HC Wainwright & Co. recently reiterating a target for Cybin Inc. (NYSE American: CYBN), pointing to an upside potential of over 2,300%, this expert endorsement underscores the significant potential Cybin holds in the market. 3. FDA Breakthrough Therapy Designation: Cybin Inc. (NYSE American: CYBN) has been granted Breakthrough Therapy Designation by the U.S. FDA for its CYB003 program. This designation is reserved for therapies showing promising early clinical results and is intended to expedite the development and review process, underscoring the potential of Cybin’s treatment for Major Depressive Disorder. 4. Pioneering Mental Health Treatments: Cybin Inc. (NYSE American: CYBN) is at the forefront of neuropsychiatry, developing next-generation therapies to address the unmet needs of those suffering from mental health conditions, including depression and anxiety disorders. Their innovative use of psychedelic-based compounds offers the potential to revolutionize treatment. 5. Cutting-Edge Research & Development: Cybin Inc. (NYSE American: CYBN) is advancing two flagship programs, CYB003 and CYB004, focused on Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), respectively. These programs demonstrate the company’s commitment to bringing innovative and safe treatment options to market. 6. Robust Clinical Pipeline: With a Phase 3 pivotal trial for CYB003 planned for late summer 2024, Cybin Inc. (NYSE American: CYBN) continues to build on the success of its Phase 2 study, which showed 75% remission from depression. The company is poised for significant advancements in clinical development with 30 clinical sites across the U.S. and Europe. 7. Strategic Intellectual Property Position: Cybin Inc. (NYSE American: CYBN) has bolstered its intellectual property portfolio, including a recently granted U.S. patent for its CYB004 program. This strategic focus on IP protection ensures long-term competitive advantage for the company’s proprietary formulations. Cybin Inc. (NYSE American: CYBN) is positioned as a standout in the mental health treatment space, gaining notable attention from industry analysts like HC Wainwright & Co., which recently reiterated a $5 target for the company. The FDA’s Breakthrough Therapy Designation for its CYB003 program highlights the promise of its treatment for Major Depressive Disorder, reflecting Cybin’s potential to bring innovative solutions to critical mental health challenges. With pioneering programs such as CYB003 and CYB004, Cybin is advancing next-generation treatments for depression and anxiety, aiming to revolutionize the field of neuropsychiatry. Supported by a robust clinical pipeline, including a Phase 3 pivotal trial for CYB003 planned for late summer 2024, the company continues to demonstrate its commitment to transforming mental health care. Cybin Inc. (NYSE American: CYBN)’s global presence and strategic partnerships enhance its ability to collaborate on groundbreaking research, while a fortified intellectual property portfolio and strong leadership team ensure the company remains at the forefront of innovation.  Backed by substantial fiscal resources, Cybin Inc. (NYSE American: CYBN) is one company you need to start your research on now. Pull up Cybin Inc. (NYSE American: CYBN) and it to your watchlist today. I’m serious. Cybin Inc. (NYSE American: CYBN) needs to be on your watchlist early this morning. There’s now under 16M shares available in the public float after the consolidation. I’ll check back in with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 09/18/2024 and ending on 09/19/2024 to publicly disseminate information about (CYBN:US) via digital communications. Headline Media LLC has been paid five thousand USD. We own zero shares of (CYBN:US). Please see important disclosure information here: https://marketcrux.com/cybn-disclosure-7812/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice